564 related articles for article (PubMed ID: 34247883)
1. IgA Nephropathy: Core Curriculum 2021.
Pattrapornpisut P; Avila-Casado C; Reich HN
Am J Kidney Dis; 2021 Sep; 78(3):429-441. PubMed ID: 34247883
[TBL] [Abstract][Full Text] [Related]
2. Update on treatment of immunoglobulin A nephropathy.
Zhang YM; Zhang H
Nephrology (Carlton); 2018 Oct; 23 Suppl 4():62-67. PubMed ID: 30298661
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and classification of IgA nephropathy.
Yu HH; Chiang BL
Autoimmun Rev; 2014; 13(4-5):556-9. PubMed ID: 24434362
[TBL] [Abstract][Full Text] [Related]
4. [Clinical and pathological manifestations of Chinese childhood patients with primary IgA nephropathy: a national collaborative study of 33 hospitals].
; Jiang XY
Zhonghua Er Ke Za Zhi; 2007 Apr; 45(4):272-8. PubMed ID: 17706064
[TBL] [Abstract][Full Text] [Related]
5. Glomerular diseases: emerging tests and therapies for IgA nephropathy.
Canetta PA; Kiryluk K; Appel GB
Clin J Am Soc Nephrol; 2014 Mar; 9(3):617-25. PubMed ID: 24071652
[TBL] [Abstract][Full Text] [Related]
6. Aberrantly glycosylated IgA1 as a factor in the pathogenesis of IgA nephropathy.
Tanaka M; Seki G; Someya T; Nagata M; Fujita T
Clin Dev Immunol; 2011; 2011():470803. PubMed ID: 21318178
[TBL] [Abstract][Full Text] [Related]
7. IgA-dominant glomerulonephritis with a membranoproliferative pattern of injury.
Andeen NK; Jefferson JA; Akilesh S; Alpers CE; Bissonnette ML; Finn LS; Higgins J; Houghton DC; Kambham N; Magil A; Najafian B; Nicosia RF; Troxell ML; Smith KD
Hum Pathol; 2018 Nov; 81():272-280. PubMed ID: 30420049
[TBL] [Abstract][Full Text] [Related]
8. Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.
Cassol CA; Bott C; Nadasdy GM; Alberton V; Malvar A; Nagaraja HN; Nadasdy T; Rovin BH; Satoskar AA
Nephrol Dial Transplant; 2020 Dec; 35(12):2123-2129. PubMed ID: 31369128
[TBL] [Abstract][Full Text] [Related]
9. [IgA nephropathy].
Floege J
Urologie; 2024 Jan; 63(1):103-111. PubMed ID: 38170257
[TBL] [Abstract][Full Text] [Related]
10. A Personalized Update on IgA Nephropathy: A New Vision and New Future Challenges.
Gutiérrez E; Carvaca-Fontán F; Luzardo L; Morales E; Alonso M; Praga M
Nephron; 2020; 144(11):555-571. PubMed ID: 32818944
[TBL] [Abstract][Full Text] [Related]
11. IgA Nephropathy.
Rodrigues JC; Haas M; Reich HN
Clin J Am Soc Nephrol; 2017 Apr; 12(4):677-686. PubMed ID: 28159829
[TBL] [Abstract][Full Text] [Related]
12. Immunostaining of galactose-deficient IgA1 by KM55 is not specific for immunoglobulin A nephropathy.
Zhao L; Peng L; Yang D; Chen S; Lan Z; Zhu X; Yuan S; Chen G; Liu Y; Liu H
Clin Immunol; 2020 Aug; 217():108483. PubMed ID: 32479989
[TBL] [Abstract][Full Text] [Related]
13. The role of complement in IgA nephropathy.
Tortajada A; Gutierrez E; Pickering MC; Praga Terente M; Medjeral-Thomas N
Mol Immunol; 2019 Oct; 114():123-132. PubMed ID: 31351413
[TBL] [Abstract][Full Text] [Related]
14. T cells in IgA nephropathy: role in pathogenesis, clinical significance and potential therapeutic target.
Ruszkowski J; Lisowska KA; Pindel M; Heleniak Z; Dębska-Ślizień A; Witkowski JM
Clin Exp Nephrol; 2019 Mar; 23(3):291-303. PubMed ID: 30406499
[TBL] [Abstract][Full Text] [Related]
15. Treatment of IgA nephropathy: Recent advances and prospects.
Coppo R
Nephrol Ther; 2018 Apr; 14 Suppl 1():S13-S21. PubMed ID: 29606258
[TBL] [Abstract][Full Text] [Related]
16. Treatment of progressive IgA nephropathy: an update.
Wang W; Chen N
Contrib Nephrol; 2013; 181():75-83. PubMed ID: 23689569
[TBL] [Abstract][Full Text] [Related]
17. [Immunoglobulin A nephropathy].
Seikrit C; Rauen T; Floege J
Internist (Berl); 2019 May; 60(5):432-439. PubMed ID: 30895344
[TBL] [Abstract][Full Text] [Related]
18. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
Li S; Li JP
Trials; 2020 Jan; 21(1):31. PubMed ID: 31907076
[TBL] [Abstract][Full Text] [Related]
19. [Considerations on the treatment of IgA nephropathy on the basis of the results of the latest studies (STOP-IgAN, TESTING, NEFIGAN)].
Nagy J; Sági B; Máté J; Vas T; Kovács T
Orv Hetil; 2017 Dec; 158(49):1946-1952. PubMed ID: 29199436
[TBL] [Abstract][Full Text] [Related]
20. The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy.
Rizk DV; Maillard N; Julian BA; Knoppova B; Green TJ; Novak J; Wyatt RJ
Front Immunol; 2019; 10():504. PubMed ID: 30941137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
